TY  - JOUR
AU  - Honda, K.
AU  - Katzke, Verena
AU  - Hüsing, A.
AU  - Okaya, S.
AU  - Shoji, H.
AU  - Onidani, K.
AU  - Olsen, A.
AU  - Tjønneland, A.
AU  - Overvad, K.
AU  - Weiderpass, E.
AU  - Vineis, P.
AU  - Muller, D.
AU  - Tsilidis, K. K.
AU  - Palli, D.
AU  - Pala, V.
AU  - Tumino, R.
AU  - Naccarati, A.
AU  - Panico, S.
AU  - Aleksandrova, K.
AU  - Boeing, H.
AU  - Bueno-de-Mesquita, H. B.
AU  - Peeters, P. H.
AU  - Trichopoulou, A.
AU  - Lagiou, P.
AU  - Khaw, K-T
AU  - Wareham, N. J.
AU  - Travis, R. C.
AU  - Merino, S.
AU  - Duell, E. J.
AU  - Rodríguez-Barranco, M.
AU  - Chirlaque, M. D.
AU  - Barricarte, A.
AU  - Rebours, V.
AU  - Boutron-Ruault, M-C
AU  - Romana Mancini, F.
AU  - Brennan, P.
AU  - Scelo, G.
AU  - Manjer, J.
AU  - Sund, M.
AU  - Öhlund, D.
AU  - Canzian, Federico
AU  - Kaaks, Rudolf
TI  - CA19-9 and Apolipoprotein-A2 isoforms as detection markers for pancreatic cancer - a prospective evaluation.
JO  - International journal of cancer
VL  - 144
IS  - 8
SN  - 0020-7136
CY  - Bognor Regis
PB  - Wiley-Liss
M1  - DKFZ-2018-01558
SP  - 1877-1887
PY  - 2019
AB  - Recently, we identified unique processing patterns of apolipoprotein A2 (ApoA2) in patients with pancreatic cancer. This study provides a first prospective evaluation of an ApoA2 isoform ('ApoA2-ATQ/AT'), alone and in combination with carbohydrate antigen 19-9 (CA19-9), as an early detection biomarker for pancreatic cancer. We performed ELISA measurements of CA19-9 and ApoA2-ATQ/AT in 156 patients with pancreatic cancer and 217 matched controls within the European EPIC cohort, using plasma samples collected up to 60 months prior to diagnosis. The detection discrimination statistics were calculated for risk scores by strata of lag-time. For CA19-9, in univariate marker analyses, C-statistics to distinguish future pancreatic cancer patients from cancer-free individuals were 0.80 for plasma taken ≤6 months before diagnosis, and 0.71 for >6-18 months; for ApoA2-ATQ/AT, C-statistics were 0.62, and 0.65, respectively. Joint models based on ApoA2-ATQ/AT plus CA19-9 significantly improved discrimination within >6-18 months (C = 0.74 vs. 0.71 for CA19-9 alone, p = 0.022) and ≤18 months (C = 0.75 vs. 0.74, p = 0.022). At 98
LB  - PUB:(DE-HGF)16
C6  - pmid:30259989
DO  - DOI:10.1002/ijc.31900
UR  - https://inrepo02.dkfz.de/record/137681
ER  -